Literature DB >> 21742052

Cytochrome P450 epoxygenase CYP2J2 attenuates nephropathy in streptozotocin-induced diabetic mice.

Guangzhi Chen1, Peihua Wang, Gang Zhao, Gang Xu, Artiom Gruzdev, Darryl C Zeldin, Dao Wen Wang.   

Abstract

Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid into epoxyeicosatrienoic acids (EETs), which play important and diverse roles in the cardiovascular system. The anti-inflammatory, anti-apoptotic, pro-angiogenic, and anti-hypertensive properties of EETs in the cardiovascular system suggest a beneficial role for EETs in diabetic nephropathy. This study investigated the effects of endothelial specific overexpression of CYP2J2 epoxygenase on diabetic nephropathy in streptozotocin-induced diabetic mice. Endothelial CYP2J2 overexpression attenuated renal damage as measured by urinary microalbumin and glomerulosclerosis. These effects were associated with inhibition of TGF-β/Smad signaling in the kidney. Indeed, overexpression of CYP2J2 prevented TGF-β1-induced renal tubular epithelial-mesenchymal transition in vitro. These findings highlight the beneficial roles of the CYP epoxygenase-EET system in the pathogenesis of diabetic nephropathy.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21742052      PMCID： PMC3215812          DOI： 10.1016/j.prostaglandins.2011.06.009

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN： 1098-8823            Impact factor:   3.072


  55 in total

1.  Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response.

Authors:  G S Ashcroft; X Yang; A B Glick; M Weinstein; J L Letterio; D E Mizel; M Anzano; T Greenwell-Wild; S M Wahl; C Deng; A B Roberts
Journal:  Nat Cell Biol       Date:  1999-09       Impact factor: 28.824

2.  Is Smad3 a major player in signal transduction pathways leading to fibrogenesis?

Authors:  A B Roberts; E Piek; E P Böttinger; G Ashcroft; J B Mitchell; K C Flanders
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

Review 3.  The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy.

Authors:  S Chen; S W Hong; M C Iglesias-de la Cruz; M Isono; A Casaretto; F N Ziyadeh
Journal:  Ren Fail       Date:  2001 May-Jul       Impact factor: 2.606

4.  The epoxyeicosatrienoic acid-stimulated phosphorylation of EGF-R involves the activation of metalloproteinases and the release of HB-EGF in cancer cells.

Authors:  Li-ming Cheng; Jian-gang Jiang; Zi-yong Sun; Chen Chen; Ryan T Dackor; Darryl C Zeldin; Dao-wen Wang
Journal:  Acta Pharmacol Sin       Date:  2010-02       Impact factor: 6.150

5.  Effect of activin A on tubulointerstitial fibrosis in diabetic nephropathy.

Authors:  Xiao-Jun Ren; Guang-ju Guan; Gang Liu; Taoyan Zhang; Gao-Hong Liu
Journal:  Nephrology (Carlton)       Date:  2009-03-10       Impact factor: 2.506

6.  Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats.

Authors:  Jeffrey J Olearczyk; Jeffrey E Quigley; Bradford C Mitchell; Tatsuo Yamamoto; In-Hae Kim; John W Newman; Ayala Luria; Bruce D Hammock; John D Imig
Journal:  Clin Sci (Lond)       Date:  2009-01       Impact factor: 6.124

7.  Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis.

Authors:  Anke C Webler; U Ruth Michaelis; Rüdiger Popp; Eduardo Barbosa-Sicard; Andiappan Murugan; John R Falck; Beate Fisslthaler; Ingrid Fleming
Journal:  Am J Physiol Cell Physiol       Date:  2008-09-11       Impact factor: 4.249

8.  C-peptide reverses TGF-beta1-induced changes in renal proximal tubular cells: implications for treatment of diabetic nephropathy.

Authors:  Claire E Hills; Nawal Al-Rasheed; Nouf Al-Rasheed; Gary B Willars; Nigel J Brunskill
Journal:  Am J Physiol Renal Physiol       Date:  2008-12-17

Review 9.  TGF-beta and fibrosis in different organs - molecular pathway imprints.

Authors:  Dirk Pohlers; Julia Brenmoehl; Ivonne Löffler; Cornelia K Müller; Carola Leipner; Stefan Schultze-Mosgau; Andreas Stallmach; Raimund W Kinne; Gunter Wolf
Journal:  Biochim Biophys Acta       Date:  2009-06-17

10.  Epoxyeicosatrienoic acids and the soluble epoxide hydrolase are determinants of pulmonary artery pressure and the acute hypoxic pulmonary vasoconstrictor response.

Authors:  Benjamin Keserü; Eduardo Barbosa-Sicard; Rüdiger Popp; Beate Fisslthaler; Alexander Dietrich; Thomas Gudermann; Bruce D Hammock; John R Falck; Norbert Weissmann; Rudi Busse; Ingrid Fleming
Journal:  FASEB J       Date:  2008-08-25       Impact factor: 5.191
View more
  20 in total

1.  Soluble epoxide hydrolase inhibitor 1-trifluoromethoxyphenyl-3- (1-propionylpiperidin-4-yl) urea attenuates bleomycin-induced pulmonary fibrosis in mice.

Authors:  Yong Zhou; Jun Yang; Guo-Ying Sun; Tian Liu; Jia-Xi Duan; Hui-Fang Zhou; Kin Sing Lee; Bruce D Hammock; Xiang Fang; Jian-Xin Jiang; Cha-Xiang Guan
Journal:  Cell Tissue Res       Date:  2015-08-28       Impact factor: 5.249

Review 2.  The Role of Cytochrome P450 Epoxygenases, Soluble Epoxide Hydrolase, and Epoxyeicosatrienoic Acids in Metabolic Diseases.

Authors:  Xizhen Xu; Rui Li; Guangzhi Chen; Samantha L Hoopes; Darryl C Zeldin; Dao Wen Wang
Journal:  Adv Nutr       Date:  2016-11-15       Impact factor: 8.701

Review 3.  Eicosanoids in metabolic syndrome.

Authors:  James P Hardwick; Katie Eckman; Yoon Kwang Lee; Mohamed A Abdelmegeed; Andrew Esterle; William M Chilian; John Y Chiang; Byoung-Joon Song
Journal:  Adv Pharmacol       Date:  2013

Review 4.  Effect of Cytochrome P450 Metabolites of Arachidonic Acid in Nephrology.

Authors:  Fan Fan; Richard J Roman
Journal:  J Am Soc Nephrol       Date:  2017-07-12       Impact factor: 10.121

5.  CYP2J2 overexpression attenuates nonalcoholic fatty liver disease induced by high-fat diet in mice.

Authors:  Guangzhi Chen; Renfan Xu; Shasha Zhang; Yinna Wang; Peihua Wang; Matthew L Edin; Darryl C Zeldin; Dao Wen Wang
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-11-11       Impact factor: 4.310

6.  CYP2J2 overexpression ameliorates hyperlipidemia via increased fatty acid oxidation mediated by the AMPK pathway.

Authors:  Shasha Zhang; Guangzhi Chen; Ning Li; Meiyan Dai; Chen Chen; Peihua Wang; Huiru Tang; Samantha L Hoopes; Darryl C Zeldin; Dao Wen Wang; Xizhen Xu
Journal:  Obesity (Silver Spring)       Date:  2015-06-05       Impact factor: 5.002

7.  Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice.

Authors:  Clothilde Roche; Dominique Guerrot; Najah Harouki; Thomas Duflot; Marie Besnier; Isabelle Rémy-Jouet; Sylvanie Renet; Anaïs Dumesnil; Annie Lejeune; Christophe Morisseau; Vincent Richard; Jeremy Bellien
Journal:  Prostaglandins Other Lipid Mediat       Date:  2015-05-27       Impact factor: 3.072

Review 8.  Orally Active Epoxyeicosatrienoic Acid Analogs.

Authors:  William B Campbell; John D Imig; James M Schmitz; John R Falck
Journal:  J Cardiovasc Pharmacol       Date:  2017-10       Impact factor: 3.105

9.  CYP2J2 overexpression increases EETs and protects against angiotensin II-induced abdominal aortic aneurysm in mice.

Authors:  Zhejun Cai; Gang Zhao; Jiangtao Yan; Wanjun Liu; Wenjing Feng; Ben Ma; Lei Yang; Jian-an Wang; Ling Tu; Dao Wen Wang
Journal:  J Lipid Res       Date:  2013-02-26       Impact factor: 5.922

10.  20-HETE and EETs in diabetic nephropathy: a novel mechanistic pathway.

Authors:  Stephanie Eid; Rita Maalouf; Ayad A Jaffa; Joseph Nassif; Ahmed Hamdy; Awad Rashid; Fuad N Ziyadeh; Assaad A Eid
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.